vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Tecnoglass Inc. (TGLS). Click either name above to swap in a different company.
Tecnoglass Inc. is the larger business by last-quarter revenue ($245.3M vs $168.4M, roughly 1.5× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 2.4%). Over the past eight quarters, Tecnoglass Inc.'s revenue compounded faster (12.8% CAGR vs 10.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Tecnoglass Inc. is a leading manufacturer of high-performance architectural glass, aluminum windows, doors, and associated building components. It primarily caters to residential and commercial construction sectors across North America and Latin America, offering custom, energy-efficient solutions for new construction and renovation projects.
ESPR vs TGLS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $245.3M |
| Net Profit | — | $26.1M |
| Gross Margin | — | 40.0% |
| Operating Margin | 50.6% | 18.3% |
| Net Margin | — | 10.6% |
| Revenue YoY | 143.7% | 2.4% |
| Net Profit YoY | — | -44.5% |
| EPS (diluted) | $0.32 | $0.57 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $245.3M | ||
| Q3 25 | $87.3M | $260.5M | ||
| Q2 25 | $82.4M | $255.5M | ||
| Q1 25 | $65.0M | $222.3M | ||
| Q4 24 | $69.1M | $239.6M | ||
| Q3 24 | $51.6M | $238.3M | ||
| Q2 24 | $73.8M | $219.7M | ||
| Q1 24 | $137.7M | $192.6M |
| Q4 25 | — | $26.1M | ||
| Q3 25 | $-31.3M | $47.2M | ||
| Q2 25 | $-12.7M | $44.1M | ||
| Q1 25 | $-40.5M | $42.2M | ||
| Q4 24 | — | $47.0M | ||
| Q3 24 | $-29.5M | $49.5M | ||
| Q2 24 | $-61.9M | $35.0M | ||
| Q1 24 | $61.0M | $29.7M |
| Q4 25 | — | 40.0% | ||
| Q3 25 | — | 42.7% | ||
| Q2 25 | — | 44.7% | ||
| Q1 25 | — | 43.9% | ||
| Q4 24 | — | 44.5% | ||
| Q3 24 | — | 45.8% | ||
| Q2 24 | — | 40.8% | ||
| Q1 24 | — | 38.8% |
| Q4 25 | 50.6% | 18.3% | ||
| Q3 25 | -11.4% | 25.1% | ||
| Q2 25 | 8.6% | 24.0% | ||
| Q1 25 | -34.0% | 26.7% | ||
| Q4 24 | -6.4% | 28.0% | ||
| Q3 24 | -31.0% | 28.4% | ||
| Q2 24 | 3.5% | 23.3% | ||
| Q1 24 | 52.5% | 21.3% |
| Q4 25 | — | 10.6% | ||
| Q3 25 | -35.9% | 18.1% | ||
| Q2 25 | -15.4% | 17.3% | ||
| Q1 25 | -62.2% | 19.0% | ||
| Q4 24 | — | 19.6% | ||
| Q3 24 | -57.2% | 20.8% | ||
| Q2 24 | -83.9% | 15.9% | ||
| Q1 24 | 44.3% | 15.4% |
| Q4 25 | $0.32 | $0.57 | ||
| Q3 25 | $-0.16 | $1.01 | ||
| Q2 25 | $-0.06 | $0.94 | ||
| Q1 25 | $-0.21 | $0.90 | ||
| Q4 24 | $-0.14 | $1.00 | ||
| Q3 24 | $-0.15 | $1.05 | ||
| Q2 24 | $-0.33 | $0.75 | ||
| Q1 24 | $0.34 | $0.63 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $104.1M |
| Total DebtLower is stronger | — | $174.4M |
| Stockholders' EquityBook value | $-302.0M | $713.1M |
| Total Assets | $465.9M | $1.3B |
| Debt / EquityLower = less leverage | — | 0.24× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $104.1M | ||
| Q3 25 | $92.4M | $127.1M | ||
| Q2 25 | $86.1M | $140.9M | ||
| Q1 25 | $114.6M | $160.2M | ||
| Q4 24 | $144.8M | $137.5M | ||
| Q3 24 | $144.7M | $124.8M | ||
| Q2 24 | $189.3M | $129.5M | ||
| Q1 24 | $226.6M | $138.8M |
| Q4 25 | — | $174.4M | ||
| Q3 25 | — | $114.7M | ||
| Q2 25 | — | $110.6M | ||
| Q1 25 | — | $110.6M | ||
| Q4 24 | — | $111.1M | ||
| Q3 24 | — | $126.8M | ||
| Q2 24 | — | $144.7M | ||
| Q1 24 | — | $160.9M |
| Q4 25 | $-302.0M | $713.1M | ||
| Q3 25 | $-451.4M | $764.0M | ||
| Q2 25 | $-433.5M | $736.0M | ||
| Q1 25 | $-426.2M | $685.1M | ||
| Q4 24 | $-388.7M | $631.2M | ||
| Q3 24 | $-370.2M | $613.3M | ||
| Q2 24 | $-344.2M | $574.8M | ||
| Q1 24 | $-294.3M | $573.6M |
| Q4 25 | $465.9M | $1.3B | ||
| Q3 25 | $364.0M | $1.2B | ||
| Q2 25 | $347.1M | $1.2B | ||
| Q1 25 | $324.0M | $1.1B | ||
| Q4 24 | $343.8M | $1.0B | ||
| Q3 24 | $314.1M | $996.3M | ||
| Q2 24 | $352.3M | $942.5M | ||
| Q1 24 | $373.1M | $981.6M |
| Q4 25 | — | 0.24× | ||
| Q3 25 | — | 0.15× | ||
| Q2 25 | — | 0.15× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.18× | ||
| Q3 24 | — | 0.21× | ||
| Q2 24 | — | 0.25× | ||
| Q1 24 | — | 0.28× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $31.0M |
| Free Cash FlowOCF − Capex | — | $11.4M |
| FCF MarginFCF / Revenue | — | 4.7% |
| Capex IntensityCapex / Revenue | 0.0% | 8.0% |
| Cash ConversionOCF / Net Profit | — | 1.19× |
| TTM Free Cash FlowTrailing 4 quarters | — | $34.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $31.0M | ||
| Q3 25 | $-4.3M | $40.0M | ||
| Q2 25 | $-31.4M | $17.9M | ||
| Q1 25 | $-22.6M | $46.9M | ||
| Q4 24 | $-35.0M | $61.1M | ||
| Q3 24 | $-35.3M | $41.5M | ||
| Q2 24 | $-7.2M | $34.5M | ||
| Q1 24 | $53.8M | $33.4M |
| Q4 25 | — | $11.4M | ||
| Q3 25 | — | $21.2M | ||
| Q2 25 | — | $-14.7M | ||
| Q1 25 | — | $16.5M | ||
| Q4 24 | — | $35.4M | ||
| Q3 24 | $-35.5M | $17.8M | ||
| Q2 24 | $-7.3M | $14.2M | ||
| Q1 24 | $53.8M | $23.6M |
| Q4 25 | — | 4.7% | ||
| Q3 25 | — | 8.2% | ||
| Q2 25 | — | -5.7% | ||
| Q1 25 | — | 7.4% | ||
| Q4 24 | — | 14.8% | ||
| Q3 24 | -68.7% | 7.5% | ||
| Q2 24 | -9.9% | 6.5% | ||
| Q1 24 | 39.0% | 12.2% |
| Q4 25 | 0.0% | 8.0% | ||
| Q3 25 | 0.0% | 7.2% | ||
| Q2 25 | 0.0% | 12.7% | ||
| Q1 25 | 0.0% | 13.7% | ||
| Q4 24 | 0.0% | 10.7% | ||
| Q3 24 | 0.3% | 9.9% | ||
| Q2 24 | 0.1% | 9.2% | ||
| Q1 24 | 0.1% | 5.1% |
| Q4 25 | — | 1.19× | ||
| Q3 25 | — | 0.85× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 1.11× | ||
| Q4 24 | — | 1.30× | ||
| Q3 24 | — | 0.84× | ||
| Q2 24 | — | 0.98× | ||
| Q1 24 | 0.88× | 1.13× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
TGLS
| Product Sales | $164.2M | 67% |
| Fixed Price Contracts | $81.1M | 33% |
| Related Party | $692.0K | 0% |
